BEROCCA PN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 36m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEROCCA PN is an injectable small-molecule nutritional/therapeutic product approved by Roche in 1947. The specific indication and mechanism of action are not documented in available data, limiting characterization of its clinical role. As a legacy injectable product, it likely serves a niche therapeutic or nutritional purpose.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); commercial team likely focused on efficiency and retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job postings are linked to this product, reflecting its mature lifecycle stage and minimal hiring. Career opportunities are limited and likely focused on retention and efficiency roles rather than growth or innovation.
Brand ManagerCommercial Operations Manager
Worked on BEROCCA PN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.